Denise Hilfiker-Kleiner

List of Publications by Year
in descending order

171 papers	15,462 citations	19657 61 h-index	18647 119 g-index
181 all docs	181 docs citations	181 times ranked	13547 citing authors

#	Article	IF	Citations
1	ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 3147-3197.	2.2	1,694
2	Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2010, 12, 767-778.	7.1	787
3	A Cathepsin D-Cleaved 16 kDa Form of Prolactin Mediates Postpartum Cardiomyopathy. Cell, 2007, 128, 589-600.	28.9	736
4	Expression of Angiotensin II and Interleukin 6 in Human Coronary Atherosclerotic Plaques. Circulation, 2000, 101, 1372-1378.	1.6	608
5	Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature, 2012, 485, 333-338.	27.8	450
6	Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. New England Journal of Medicine, 2016, 374, 233-241.	27.0	432
7	Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum Cardiomyopathy. Circulation, 2010, 121, 1465-1473.	1.6	429
8	Sex differences in heart failure. European Heart Journal, 2019, 40, 3859-3868c.	2.2	406
9	MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. Journal of Clinical Investigation, 2013, 123, 2143-2154.	8.2	400
10	Signal Transducer and Activator of Transcription 3 Is Required for Myocardial Capillary Growth, Control of Interstitial Matrix Deposition, and Heart Protection From Ischemic Injury. Circulation Research, 2004, 95, 187-195.	4.5	345
11	The myocardial JAK/STAT pathway: From protection to failure. , 2008, 120, 172-185.		304
12	Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. European Heart Journal, 2006, 27, 441-446.	2.2	273
13	Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Research in Cardiology, 2013, 108, 366.	5.9	266
14	Cardioprotection by Ischemic Postconditioning Is Lost in Aged and STAT3-Deficient Mice. Circulation Research, 2008, 102, 131-135.	4.5	257
15	Role of NAD(P)H Oxidase in Angiotensin IIâ€“Induced JAK/STAT Signaling and Cytokine Induction. Circulation Research, 2000, 87, 1195-1201.	4.5	256
16	Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. European Heart Journal, 2017, 38, 2671-2679.	2.2	243
17	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2019, 21, 827-843.	7.1	223
18	Peripartum cardiomyopathy: current management and future perspectives. European Heart Journal, 2015, 36, 1090-1097.	2.2	196

#	Article	IF	Citations
19	Pathophysiology and epidemiology of peripartum cardiomyopathy. Nature Reviews Cardiology, 2014, 11, 364-370.	13.7	194
20	Allopurinol Attenuates Left Ventricular Remodeling and Dysfunction After Experimental Myocardial Infarction. Circulation, 2004, 110, 2175-2179.	1.6	188
21	Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis. Basic Research in Cardiology, 2007, 102, 393-411.	5.9	172
22	Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. European Heart Journal, 2014, 35, 932-941.	2.2	167
23	Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (<scp>PPCM</scp>). European Journal of Heart Failure, 2017, 19, 1131-1141.	7.1	163
24	Reversal of IFNâ€Î³, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. European Journal of Heart Failure, 2008, 10, 861-868.	7.1	162
25	Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2016, 18, 1096-1105.	7.1	160
26	Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. European Heart Journal, 2014, 35, 2165-2173.	2.2	159
27	Continuous Glycoprotein-130â€“Mediated Signal Transducer and Activator of Transcription-3 Activation Promotes Inflammation, Left Ventricular Rupture, and Adverse Outcome in Subacute Myocardial Infarction. Circulation, 2010, 122, 145-155.	1.6	140
28	Alterations in Janus Kinase (JAK)-Signal Transducers and Activators of Transcription (STAT) Signaling in Patients With End-Stage Dilated Cardiomyopathy. Circulation, 2003, 107, 798-802.	1.6	135
29	Regulation and function of endothelial glycocalyx layer in vascular diseases. Vascular Pharmacology, 2018, 100, 26-33.	2.1	128
30	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	2.2	123
31	Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. Heart, 2013, 99, 308-313.	2.9	121
32	Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular functionâ€"value of the wearable cardioverter/defibrillator. European Journal of Heart Failure, 2014, 16, 1331-1336.	7.1	121
33	Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. European Heart Journal, 2011, 32, 1287-1297.	2.2	119
34	Molecular Mechanisms in Heart Failure. Journal of the American College of Cardiology, 2006, 48, A56-A66.	2.8	118
35	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. European Journal of Heart Failure, 2018, 20, 445-459.	7.1	118
36	Preclinical Testing of Tissue-Engineered Heart Valves Re-Endothelialized Under Simulated Physiological Conditions. Circulation, 2006, 114, I559-65.	1.6	115

#	Article	IF	Citations
37	Role of interleukinâ€6 for left ventricular remodeling and survival after experimental myocardial infarction. FASEB Journal, 2003, 17, 1-20.	0.5	113
38	Nebivolol Exerts Beneficial Effects on Endothelial Function, Early Endothelial Progenitor Cells, Myocardial Neovascularization, and Left Ventricular Dysfunction Early After Myocardial Infarction Beyond Conventional Î²1-Blockade. Journal of the American College of Cardiology, 2011, 57, 601-611.	2.8	111
39	Regulation of Proangiogenic Factor CCN1 in Cardiac Muscle. Circulation, 2004, 109, 2227-2233.	1.6	104
40	Expression of CYR61, an Angiogenic Immediate Early Gene, in Arteriosclerosis and Its Regulation by Angiotensin II. Circulation, 2002, 106, 254-260.	1.6	103
41	Recovery From Postpartum Cardiomyopathy in 2 Patients by Blocking Prolactin Release With Bromocriptine. Journal of the American College of Cardiology, 2007, 50, 2354-2355.	2.8	103
42	Longâ€term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2018, 20, 951-962.	7.1	101
43	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. European Heart Journal, 2020, 41, 3787-3797.	2.2	101
44	Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models. Nature Medicine, 2015, 21, 601-609.	30.7	100
45	Many good reasons to have STAT3 in the heart. , 2005, 107, 131-137.		99
46	<scp>EURObservational</scp> Research Programme: a worldwide registry on peripartum cardiomyopathy (<scp>PPCM</scp>) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on <scp>PPCM</scp>. European Journal of Heart Failure, 2014, 16, 583-591.	7.1	99
47	Mental disorders in adults with congenital heart disease: Unmet needs and impact on quality of life. Journal of Affective Disorders, 2016, 204, 180-186.	4.1	93
48	Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovascular Research, 2018, 114, 1287-1303.	3.8	91
49	Peripartum Cardiomyopathy: Recent Insights in its Pathophysiology. Trends in Cardiovascular Medicine, 2008, 18, 173-179.	4.9	90
50	Targeting myocardial remodelling to develop novel therapies for heart failure. European Journal of Heart Failure, 2014, 16, 494-508.	7.1	90
51	oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4. Journal of Molecular and Cellular Cardiology, 2014, 66, 72-82.	1.9	89
52	Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. European Journal of Heart Failure, 2017, 19, 1723-1728.	7.1	88
53	Low STAT3 expression sensitizes to toxic effects of Î²-adrenergic receptor stimulation in peripartum cardiomyopathy. European Heart Journal, 2017, 38, ehw086.	2.2	87
54	STAT3 and cardiac remodeling. Heart Failure Reviews, 2011, 16, 35-47.	3.9	84

#	Article	IF	Citations
55	STAT3, a key regulator of cell-to-cell communication in the heart. Cardiovascular Research, 2014, 102, 281-289.	3.8	84
56	Increased Collagen Deposition and Diastolic Dysfunction but Preserved Myocardial Hypertrophy After Pressure Overload in Mice Lacking PKCÎµ. Circulation Research, 2005, 96, 748-755.	4.5	81
57	An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 216-227.	7.1	81
58	Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovascular Research, 2015, 106, 365-374.	3.8	80
59	Long-term outcome of Peripartum cardiomyopathy in a population with high seropositivity for Human Immunodeficiency Virus. International Journal of Cardiology, 2011, 147, 202-208.	1.7	75
60	Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress. Cardiovascular Research, 2014, 101, 587-596.	3.8	73
61	Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clinical Research in Cardiology, 2020, 109, 1197-1222.	3.3	71
62	Erythropoietin Preserves the Endothelial Differentiation Capacity of Cardiac Progenitor Cells and Reduces Heart Failure during Anticancer Therapies. Cell Stem Cell, 2011, 9, 131-143.	11.1	68
63	Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. Clinical Research in Cardiology, 2017, 106, 582-589.	3.3	67
64	Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. Circulation, 2021, 143, 1852-1862.	1.6	65
65	Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study. ESC Heart Failure, 2015, 2, 139-149.	3.1	62
66	Lack of JunD Promotes Pressure Overloadâ€“Induced Apoptosis, Hypertrophic Growth, and Angiogenesis in the Heart. Circulation, 2005, 112, 1470-1477.	1.6	60
67	A positive feedback loop between IL-1Î², LPS and NEU1 may promote atherosclerosis by enhancing a pro-inflammatory state in monocytes and macrophages. Vascular Pharmacology, 2018, 103-105, 16-28.	2.1	59
68	STAT3-Mediated Activation of Myocardial Capillary Growth. Trends in Cardiovascular Medicine, 2005, 15, 152-157.	4.9	58
69	Peripartum cardiomyopathyâ€”a new treatment option by inhibition of prolactin secretion. American Journal of Obstetrics and Gynecology, 2008, 199, e5-e6.	1.3	58
70	Circulating microparticles as indicators of peripartum cardiomyopathy. European Heart Journal, 2012, 33, 1469-1479.	2.2	56
71	Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy. Clinical Research in Cardiology, 2015, 104, 911-917.	3.3	55
72	Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy. Basic Research in Cardiology, 2015, 110, 60.	5.9	51

#	Article	IF	Citations
73	Longâ€term followâ€up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular coâ€morbidities. European Journal of Heart Failure, 2019, 21, 1534-1542.	7.1	51
74	In vitro maturation of large-scale cardiac patches based on a perfusable starter matrix by cyclic mechanical stimulation. Acta Biomaterialia, 2016, 30, 177-187.	8.3	50
75	Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. PLoS ONE, 2021, 16, e0255335.	2.5	48
76	Reviewing peripartum cardiomyopathy: current state of knowledge. Future Cardiology, 2009, 5, 175-189.	1.2	47
77	Prolactin: a new therapeutic target in peripartum cardiomyopathy. Heart, 2010, 96, 1352-1357.	2.9	47
78	Small molecule-mediated refolding and activation of myosin motor function. ELife, 2014, 3, e01603.	6.0	47
79	MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. Circulation, 2016, 134, 1973-1990.	1.6	46
80	Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 173-182.	1.0	43
81	16-kDa Prolactin and Bromocriptine in Postpartum Cardiomyopathy. Current Heart Failure Reports, 2012, 9, 174-182.	3.3	42
82	Neuraminidase-1 promotes heart failure after ischemia/reperfusion injury by affecting cardiomyocytes and invading monocytes/macrophages. Basic Research in Cardiology, 2020, 115, 62.	5.9	41
83	Electrophysiological abnormalities in induced pluripotent stem cellâ€derived cardiomyocytes generated from Duchenne muscular dystrophy patients. Journal of Cellular and Molecular Medicine, 2019, 23, 2125-2135.	3.6	39
84	Peripartum cardiomyopathy: from genetics to management. European Heart Journal, 2021, 42, 3094-3102.	2.2	39
85	Macrophage Mineralocorticoid Receptor Is a Pleiotropic Modulator of Myocardial Infarct Healing. Hypertension, 2019, 73, 102-111.	2.7	38
86	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2021, 23, 527-540.	7.1	37
87	Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression. JCI Insight, 2017, 2, .	5.0	37
88	JunD attenuates phenylephrine-mediated cardiomyocyte hypertrophy by negatively regulating AP-1 transcriptional activity. Cardiovascular Research, 2006, 71, 108-117.	3.8	35
89	Myofilament Remodeling and Function Is More Impaired in Peripartum Cardiomyopathy Compared with Dilated Cardiomyopathy and Ischemic Heart Disease. American Journal of Pathology, 2017, 187, 2645-2658.	3.8	35
90	Early ivabradine treatment in patients with acute peripartum cardiomyopathy: Subanalysis of the German PPCM registry. International Journal of Cardiology, 2016, 216, 165-167.	1.7	34

#	Article	IF	Citations
91	Telemonitoring-supported exercise training, metabolic syndrome severity, and work ability in company employees: a randomised controlled trial. Lancet Public Health, The, 2019, 4, e343-e352.	10.0	34
92	Peripartum cardiomyopathy: basic mechanisms and hope for new therapies. Cardiovascular Research, 2020, 116, 520-531.	3.8	33
93	STAT3 regulation of and by microRNAs in development and disease. Jak-stat, 2012, 1, 143-150.	2.2	32
94	Improvement of biological age by physical activity. International Journal of Cardiology, 2014, 176, 1187-1189.	1.7	32
95	Dissecting the target leukocyte subpopulations of clinically relevant inflammation radiopharmaceuticals. Journal of Nuclear Cardiology, 2021, 28, 1636-1645.	2.1	32
96	Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports. Journal of Medical Case Reports, 2010, 4, 80.	0.8	31
97	Increased Cancer Prevalence in Peripartum Cardiomyopathy. JACC: CardioOncology, 2019, 1, 196-205.	4.0	30
98	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2022, 118, 3016-3051.	3.8	30
99	Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction. Clinical Research in Cardiology, 2019, 108, 290-297.	3.3	29
100	Expression of fibulin-6 in failing hearts and its role for cardiac fibroblast migration. Cardiovascular Research, 2014, 103, 509-520.	3.8	25
101	Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy. Cardiovascular Research, 2017, 113, cvw245.	3.8	23
102	Pathophysiology and risk factors of peripartum cardiomyopathy. Nature Reviews Cardiology, 2022, 19, 555-565.	13.7	21
103	Protective Function of STAT3 in CVB3-Induced Myocarditis. Cardiology Research and Practice, 2012, 2012, 1-11.	1.1	20
104	Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. Leukemia, 2019, 33, 1313-1323.	7.2	20
105	In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles. Cardiovascular Research, 2020, 116, 1875-1886.	3.8	20
106	Assessment of major mental disorders in a German peripartum cardiomyopathy cohort. ESC Heart Failure, 2020, 7, 4394-4398.	3.1	20
107	Bromocriptine for the Treatment of Peripartum Cardiomyopathy. Cardiac Failure Review, 2018, 4, 1.	3.0	18
108	Late onset heart failure after childhood chemotherapy. European Heart Journal, 2019, 40, 798-800.	2.2	18

#	Article	IF	Citations
109	Outcome in German and South African peripartum cardiomyopathy cohorts associates with medical therapy and fibrosis markers. ESC Heart Failure, 2020, 7, 512-522.	3.1	18
110	miRâ^'21 and NT-proBNP Correlate with Echocardiographic Parameters of Atrial Dysfunction and Predict Atrial Fibrillation. Journal of Clinical Medicine, 2020, 9, 1118.	2.4	18
111	Modulation of cardiac AKT and STAT3 signalling in preclinical cancer models and their impact on the heart. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118519.	4.1	17
112	Postpartum Cardiomyopathy. Deutsches Ärzteblatt International, 2008, 105, 751-6.	0.9	17
113	Common genetic predisposition for heart failure and cancer. Herz, 2020, 45, 632-636.	1.1	16
114	Loss of vascular endothelial notch signaling promotes spontaneous formation of tertiary lymphoid structures. Nature Communications, 2022, 13, 2022.	12.8	16
115	Pregnancy and Heart Disease: Pregnancy-Associated Hypertension and Peripartum Cardiomyopathy. Current Problems in Cardiology, 2018, 43, 364-388.	2.4	15
116	Fluoxetine induces glucose uptake and modifies glucose transporter palmitoylation in human peripheral blood mononuclear cells. Expert Opinion on Therapeutic Targets, 2019, 23, 883-891.	3.4	15
117	Cardiovascular Disorders in Pregnancy: Diagnosis and Management. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2013, 27, 821-834.	2.8	14
118	Effects of personalized endurance training on cellular age and vascular function in middle-aged sedentary women. European Journal of Preventive Cardiology, 2019, 26, 1903-1906.	1.8	14
119	Complete recovery of fulminant peripartum cardiomyopathy on mechanical circulatory support combined with highâ€dose bromocriptine therapy. ESC Heart Failure, 2017, 4, 641-644.	3.1	13
120	Management of peripartum cardiomyopathy. Current Heart Failure Reports, 2008, 5, 238-244.	3.3	12
121	Olanzapine and aripiprazole differentially affect glucose uptake and energy metabolism in human mononuclear blood cells. Journal of Psychiatric Research, 2017, 88, 18-27.	3.1	12
122	ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy. Circulation: Heart Failure, 2021, 14, e006898.	3.9	12
123	Dnmt3a-mediated inhibition of Wnt in cardiac progenitor cells improves differentiation and remote remodeling after infarction. JCI Insight, 2017, 2, .	5.0	12
124	TNFÎ± decreases Î±MHC expression by a NO mediated pathway: role of E-box transcription factors for cardiomyocyte specific gene regulation. Cardiovascular Research, 2002, 53, 460-469.	3.8	11
125	Employers With Metabolic Syndrome and Increased Depression/Anxiety Severity Profit Most From Structured Exercise Intervention for Work Ability and Quality of Life.. Frontiers in Psychiatry, 2020, 11, 562.	2.6	11
126	Anthracycline-free tumor elimination in mice leads toÂfunctional and molecular cardiac recovery from cancer-induced alterations in contrast to long-lasting doxorubicin treatment effects. Basic Research in Cardiology, 2021, 116, 61.	5.9	11

#	Article	IF	Citations
127	Disease-Modifying Mutations in Familial Hypertrophic Cardiomyopathy. Circulation, 2008, 117, 1775-1777.	1.6	10
128	Peripartum cardiomyopathy. Current Opinion in Critical Care, 2013, 19, 397-403.	3.2	10
129	Animal Models of Cardiovascular Complications of Pregnancy. Circulation Research, 2022, 130, 1763-1779.	4.5	10
130	Left bundle branch block during pregnancy as a sign of imminent peripartum cardiomyopathy. European Heart Journal, 2011, 32, 1076-1076.	2.2	8
131	Human iPSC-Derived Cardiomyocytes of Peripartum Patients With Cardiomyopathy Reveal Aberrant Regulation of Lipid Metabolism. Circulation, 2020, 142, 2288-2291.	1.6	8
132	cUMP hydrolysis by PDE3A. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 269-280.	3.0	7
133	Cardiomyocytes display low mitochondrial priming and are highly resistant toward cytotoxic Tâ€cell killing. European Journal of Immunology, 2016, 46, 1415-1426.	2.9	6
134	Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. Clinical and Translational Gastroenterology, 2021, 12, e00371.	2.5	6
135	Effects of six month personalized endurance training on work ability in middle-aged sedentary women: a secondary analysis of a randomized controlled trial. Journal of Occupational Medicine and Toxicology, 2020, 15, 8.	2.2	5
136	Perhexiline treatment improves toxic effects of Î²â€adrenergic receptor stimulation in experimental peripartum cardiomyopathy. ESC Heart Failure, 2021, 8, 3375-3381.	3.1	5
137	Focus on pregnancy-mediated heart and vascular disease. Cardiovascular Research, 2014, 101, 543-544.	3.8	4
138	miR-125b regulates chemotaxis and survival of bone marrow derived granulocytes in vitro and in vivo. PLoS ONE, 2018, 13, e0204942.	2.5	4
139	Stable depletion of RUNX1-ETO in Kasumi-1 cells induces expression and enhanced proteolytic activity of Cathepsin G and Neutrophil Elastase. PLoS ONE, 2019, 14, e0225977.	2.5	4
140	Future cardiovascular risk prediction in women with pregnancy complications: the HUNT is on. European Heart Journal, 2019, 40, 1121-1123.	2.2	3
141	Cardiology and cardiovascular research in Germany: 5Âyears of gender demographics. Clinical Research in Cardiology, 2019, 108, 218-220.	3.3	3
142	Increased prostaglandin-D2 in male STAT3-deficient hearts shifts cardiac progenitor cells from endothelial to white adipocyte differentiation. PLoS Biology, 2020, 18, e3000739.	5.6	3
143	Cardiomyopathies and Congenital Heart Disease in Pregnancy. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1256-1261.	1.8	2
144	Reply to â€˜Bromocriptine for the treatment of peripartum cardiomyopathy: comparison of outcome with a nationwide Danish cohortâ€™. European Heart Journal, 2018, 39, 3478-3478.	2.2	2

#	Article	IF	Citations
145	MYOCARDIAL AUTOANTIBODIES AND THEIR CLINICAL SIGNIFICANCE. , 2007, , 355-365.		1
146	Article Commentary: Acute Heart Failure: Is it Peripartum Cardiomyopathy or Not?. Obstetric Medicine, 2013, 6, 42-44.	1.1	1
147	Data on left ventricular expression of STAT3 and AKT in transgenic mouse models with B16F10 melanoma. Data in Brief, 2019, 26, 104508.	1.0	1
148	Breastfeeding in Patients With HeartÂFailure. JACC Basic To Translational Science, 2019, 4, 866-867.	4.1	1
149	Etiology and pathophysiology. , 2021, , 1-11.		1
150	The STAT3 Pathway and Downstream Mechanisms in Cardiac Remodeling: Friend or Foe. , 2013, , 347-364.		1
151	Low-dose Erythropoietin reduces risk of heart failure induced by anti-cancer therapy. Oncotarget, 2011, 2, 825-825.	1.8	1
152	High prevalence of reduced fertility and use of assisted reproductive technology in a German cohort of patients with peripartum cardiomyopathy. Clinical Research in Cardiology, 2022, , 1.	3.3	1
153	Comparison of the American PPCM RegistryÂData With International Registries. Journal of the American College of Cardiology, 2016, 67, 733-734.	2.8	0
154	Letter by Hilfiker-Kleiner et al Regarding Article, â€œModeling Peripartum Cardiomyopathy With Human Induced Pluripotent Stem Cells Reveals Distinctive Abnormal Function of Cardiomyocytesâ€. Circulation, 2019, 139, e990-e991.	1.6	0
155	Comorbidities and Co-Existing Conditions in Heart Failure Around Pregnancy. Cardiovascular Medicine, 2019, , 63-70.	0.0	0
156	Editorial commentary: Peripartum cardiomyopathy: Long-term implications of treatment and management. Trends in Cardiovascular Medicine, 2019, 29, 174-175.	4.9	0
157	What needs to be known about longer-term management and prognosis?. , 2021, , 45-65.		0
158	Peripartum Cardiomyopathy: Role of STAT-3 and Reactive Oxygen Species. , 2010, , 317-337.		0
159	Mirâˆ¼17-92 Identifies BCL2 As a Therapeutic Target In BCR-ABL Positive B-Lineage Acute Lymphoblastic Leukemia. Blood, 2013, 122, 835-835.	1.4	0
160	Schwangerschaftsassoziierte Kardiomyopathie. , 2015, , 1-13.		0
161	Stable Silencing of RUNX1/ETO Induces Expression of a Shortened PU.1 Variant in t(8;21) Kasumi Cells. Blood, 2016, 128, 2716-2716.	1.4	0
162	Cardiomyopathies in Women. , 2017, , 127-139.		0

#	Article	IF	Citations
163	Optimized Induction of Mitochondrial Apoptosis By Combination Therapies with Venetoclax for Chemotherapy-Free Treatment of BCR-ABL+ Acute Lymphoblastic Leukemia in Preclinical Models. Blood, 2018, 132, 4025-4025.	1.4	0
164	Natriuretic Peptide Receptor 1, a Novel Player in Peripartum Heart Failure. Circulation, 2020, 141, 589-591.	1.6	0
165	Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart. Cancers, 2022, 14, 983.	3.7	0
166	Title is missing!. , 2020, 18, e3000739.		0
167	Title is missing!. , 2020, 18, e3000739.		0
168	Title is missing!. , 2020, 18, e3000739.		0
169	Title is missing!. , 2020, 18, e3000739.		0
170	Title is missing!. , 2020, 18, e3000739.		0
171	Title is missing!. , 2020, 18, e3000739.		0